CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

BACKGROUND: Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendrinou, Effrosyni, Mashaly, Mohamed Elsayed, Al Okily, Amir Mohamed, Mohamed, Mohamed Elsayed, Refaie, Ayman Fathi, Elsawy, Essam Mahmoud, Saleh, Hazem Hamed, Sheashaa, Hussein, Patrinos, George P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431691/
https://www.ncbi.nlm.nih.gov/pubmed/32848803
http://dx.doi.org/10.3389/fphar.2020.01218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431691/
https://www.ncbi.nlm.nih.gov/pubmed/32848803
http://dx.doi.org/10.3389/fphar.2020.01218

Ejemplares similares